New indications for treatment of chronic inflammation by TNF-α blockade

Research output: Contribution to journalArticlepeer-review

82 Scopus citations


The impressive anti-inflammatory effects of the tumor necrosis factor (TNF)α blockers etanercept and infliximab have led to their use in multiple inflammatory diseases besides their original indication, rheumatoid arthritis (RA). The well-studied clinical effects of both agents in RA are the reduction of signs and symptoms of joint inflammation as well as the arrest of bone destruction. Infliximab has also been Food and Drug Administration-approved in the treatment of Crohn disease; etanercept is now FDA-approved for juvenile chronic arthritis and psoriatic arthritis. Favorable initial clinical trials have been reported in other rheumatic diseases, including ankylosing spondylitis and adult Still disease. In addition, TNFα blockade is being studied in the treatment of uveitis, myelodysplastic syndromes, and graft-versus-host disease. Studies in sepsis and septic shock have identified small subsets of patients that may benefit from TNFα blockade, but broader use in septic patients has not improved survival. The TNFα blockers have had relatively infrequent serious side effects, especially compared with the immunosuppressive and cytotoxic agents otherwise employed to treat these diseases. Further studies of optimal dosing, combination with other therapies, and long-term benefits and side effects will emerge from future trials.

Original languageEnglish (US)
Pages (from-to)75-92
Number of pages18
JournalAmerican Journal of the Medical Sciences
Issue number2
StatePublished - Feb 1 2003


  • Arthritis
  • Etanercept
  • Inflammation
  • Infliximab
  • TNFα

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'New indications for treatment of chronic inflammation by TNF-α blockade'. Together they form a unique fingerprint.

Cite this